Volume 11, Number 3, March 2005

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Nigel J. Temperton,* Paul K. Chan,† Graham Simmons,‡ Maria C. Zambon,§ Richard S. Tedder,* Yasuhiro Takeuchi,* and Robin A. Weiss*
*University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; and §Health Protection Agency Central Public Health Laboratory, London, United Kingdom

Figure 1. Infectivity of retroviral severe acute respiratory syndrome–associated coronavirus (SARS-CoV) spike protein (S) pseudotypes on target cells. SARS-CoV S-mediated infection of human 293T, TE671, and quail QT6/ACE2 was assessed. Murine leukemia virus (MLV) or HIV pseudotypes bearing either the pantropic vesicular stomatitis virus envelope protein (VSV-G) as a positive control, or the SARS-CoV S, were added to target cells. After 72 h, green fluorescent protein (GFP)–positive cells were counted by fluorescence-activated cell sorter analysis. Infection titers are given as infectious units per milliliter (IU/mL). Arrow indicates that infection titer was less than the detection limit, 10² IU/mL.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed February 17, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention